Oxana Beskrovnaya - 03 Jan 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Scientific Officer
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
03 Jan 2024
Net transactions value
-$1,559,945
Form type
4
Filing time
04 Jan 2024, 21:48:23 UTC
Previous filing
12 Dec 2023
Next filing
11 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $46,686 +45,326 +26% $1.03* 221,911 03 Jan 2024 Direct F1
transaction DYN Common Stock Sale $282,106 -15,382 -6.9% $18.34 206,529 03 Jan 2024 Direct F1, F2, F3
transaction DYN Common Stock Sale $468,306 -24,583 -12% $19.05 181,946 03 Jan 2024 Direct F1, F2, F4
transaction DYN Common Stock Sale $109,900 -5,361 -2.9% $20.50 176,585 03 Jan 2024 Direct F1, F2, F5
transaction DYN Common Stock Options Exercise $23,354 +22,674 +13% $1.03* 199,259 04 Jan 2024 Direct F1
transaction DYN Common Stock Sale $769,673 -42,453 -21% $18.13 156,806 04 Jan 2024 Direct F1, F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock option (right to buy) Options Exercise $0 -45,326 -46% $0.000000 53,100 03 Jan 2024 Common Stock 45,326 $1.03 Direct F7
transaction DYN Stock option (right to buy) Options Exercise $0 -22,674 -43% $0.000000 30,426 04 Jan 2023 Common Stock 22,674 $1.03 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 146,805 unvested RSUs.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.56, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.45, inclusive.
F7 The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter.